²é¿´: 3950  |  »Ø¸´: 16
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

wachina

ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)

[½»Á÷] ÎäÌïfasiglifam (TAK-875)Ðû¸æÊ§°Ü£¬ºãÈðß»¸ñÁзº³ÝÍö´½º® ÒÑÓÐ16È˲ÎÓë

Takeda terminates development activities for fasiglifam (TAK-875)



Takeda Pharmaceutical Company Limited (Takeda) announced that it has decided voluntarily to terminate the development activities for fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety.



Patient safety is Takeda's highest priority. The company has worked with three independent panels of experts to provide for the safety of trial participants and ensure independent safety oversight for the clinical trials throughout the duration of the fasiglifam (TAK-875) Phase 3 development program.



The expert panels include the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program, reviews the unblinded clinical data from program trials and provides continual safety oversight of trial subjects and recommendations. The DMC is comprised of clinical experts in endocrinology, cardiology and hepatology as well as a statistician. The independent Liver Safety Evaluation Committee (LSEC) is comprised of five hepatologists with expertise in drug-induced liver injury. While remaining blinded to treatment information, the LSEC regularly evaluates data on liver enzymes elevations and adjudicates cases that impacted the liver. In addition, an independent Executive Committee (EC) provides additional oversight for the fasiglifam (TAK-875) cardiovascular outcomes trial.



After careful consideration of the data emerging from all the clinical trials and in consultation with these panels, the company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks. For this reason, Takeda has decided voluntarily to terminate the development activities for fasiglifam.
×÷ΪÂýÐÔ¼²²¡£ºÌÇÄò²¡µÄÖÎÁÆ£¬¸Î¶¾ÐÔÌ«ÖÂÃüÁË£¬ÄѹÖÎäÌï»ÓÀáÕ¶ÂíÚÕ¡£ÖµµÃÒ»ÌáµÄÊÇ£¬ºãÈðÒ²ÏòCFDAÉ걨ÁËGPR-40¼¤¶¯¼Áß»¸ñÁзº£¬ÏÖÔÚÐÄÀï¹À¼ÆÒ²ÊǰÎÁ¹°ÎÁ¹µÄ
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wph75623

Í­³æ (СÓÐÃûÆø)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÌÇÄò²¡ÈçºÎÖÎÁÆ£¬²¡ÒòÈçºÎ£¬ÈÔÊÇδ֪µÄ£¬ÕâÑùµÄ´úлÎÉÂÒ¼²²¡ÆäʵÊÇ»úÌåÄÚÔ๦ÄÜʧµ÷µÄ±íÏÖ£¬Ä¿Ç°Î÷Ò©¶¼ÊÇÖα겻Öα¾£¬Ñо¿ÄÜÖÎÓú¸Ã¼²²¡µÄÒ©Îï²ÅÊÇÖÕ¼«Ä¿±ê£¬ÏÖÔÚµÄÒ©¶¼ÊÇÔÚ³­¸ö°ÐµãµÄ¸ÅÄ¶Ô»¼ÕßÄÑÓÐʵÔÚµÄÒæ´¦
4Â¥2013-12-30 16:49:55
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 17 ¸ö»Ø´ð

jinshanshi88

ľ³æ (ÖøÃûдÊÖ)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ºãÈðÕâϱ¯¾çÁË£¡
»¹²»Èç׳ʿ¶ÏÍ󣬷ñÔòÔ½×ßÔ½Ô¶
2Â¥2013-12-30 12:41:43
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

guri

Ìú³æ (³õÈëÎÄ̳)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ß»¸ñÁзºÖ»ÊǺãÈð¹ÜÏßÖеÄÒ»¸öÁÙ´²»¯ºÏÎӦ¸Ã¿ÉÒÔ¸îÉáµô¡£µ¹ÊÇÕû¸öÌÇÄò²¡ÁìÓò¾Íû¿´µ½ÕæÕýºÃµÄае㣬ÕâÊǷdz£ÖµµÃÓÇÂǵġ£¡£¡£
3Â¥2013-12-30 13:06:43
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
°¥£¡£¡£¡£¡£¡£¡£¡
5Â¥2013-12-30 17:02:55
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á +9 ÄÝÄÝninicgb 2026-03-15 13/650 2026-03-19 22:13 by l1006507827
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄϾ©Àí¹¤´óѧ085701×ÊÔ´Óë»·¾³302·ÖÇóµ÷¼Á +3 ¿ûè÷ÎÀ¶Ó 2026-03-18 5/250 2026-03-19 19:35 by ¸øÄãÄã×¢ÒâÐÝÏ¢
[¿¼ÑÐ] 288Çóµ÷¼Á£¬Ò»Ö¾Ô¸»ªÄÏÀí¹¤´óѧ071005 +5 ioodiiij 2026-03-17 5/250 2026-03-19 18:22 by zcl123
[¿¼ÑÐ] ²ÄÁÏ¿¼Ñе÷¼Á +3 xwt¡£ 2026-03-19 3/150 2026-03-19 11:22 by wãåÑôw
[¿¼ÑÐ] ±¾¿ÆÖ£ÖÝ´óѧÎïÀíѧԺ£¬Ò»Ö¾Ô¸»ª¿Æ070200ѧ˶£¬346Çóµ÷¼Á +4 ÎÒ²»ÊÇÒ»¸ù´Ð 2026-03-18 4/200 2026-03-19 09:11 by ¸¡ÔÆ166
[¿¼ÑÐ] 297Çóµ÷¼Á +8 Ï·¾«µ¤µ¤µ¤ 2026-03-17 8/400 2026-03-18 14:30 by laoshidan
[¿¼ÑÐ] ²ÄÁÏר˶306Ó¢Ò»Êý¶þ +10 z1z2z3879 2026-03-16 13/650 2026-03-18 14:20 by 007_lilei
[¿¼ÑÐ] 0703»¯Ñ§Çóµ÷¼Á ×Ü·Ö331 +3 ZY-05 2026-03-13 3/150 2026-03-18 10:58 by macy2011
[¿¼ÑÐ] 268Çóµ÷¼Á +6 ¼òµ¥µã0 2026-03-17 6/300 2026-03-18 09:04 by Î޼ʵIJÝÔ­
[»ù½ðÉêÇë] ±»ÎÒÑÔÖУºÐÂÄ£°å²»Ç¿µ÷¸ñʽÁË£¬¼Ùר¼Ò¿ªÊ¼¹Ü¸ñʽÁË +4 beefly 2026-03-14 4/200 2026-03-17 22:04 by »ÆÄñÓÚ·ÉChao
[¿¼ÑÐ] ¿¼Ñл¯Ñ§Ñ§Ë¶µ÷¼Á£¬Ò»Ö¾Ô¸985 +4 ÕÅvvvv 2026-03-15 6/300 2026-03-17 17:15 by ruiyingmiao
[¿¼ÑÐ] 308Çóµ÷¼Á +4 ÊÇLupa°¡ 2026-03-16 4/200 2026-03-17 17:12 by ruiyingmiao
[¿¼ÑÐ] »úеר˶325£¬Ñ°ÕÒµ÷¼ÁԺУ +3 y9999 2026-03-15 5/250 2026-03-16 19:58 by y9999
[¿¼ÑÐ] 0703Ò»Ö¾Ô¸211 285·ÖÇóµ÷¼Á +5 ly3471z 2026-03-13 5/250 2026-03-16 16:16 by ŶŶ123
[¿¼ÑÐ] 0703 ÎïÀí»¯Ñ§µ÷¼Á +3 ÎÒ¿ÉÒÔÉϰ¶µÄ¶Ô 2026-03-13 5/250 2026-03-16 10:50 by ÎÒ¿ÉÒÔÉϰ¶µÄ¶ÔÂ
[¿¼ÑÐ] 070305Çóµ÷¼Á +3 mlpqaz03 2026-03-14 4/200 2026-03-15 11:04 by peike
[¿¼ÑÐ] 297Ò»Ö¾Ô¸ÉϽ»085600Çóµ÷¼Á +5 Ö¸¼â°ËǧÀï 2026-03-14 5/250 2026-03-14 17:26 by a²»Ò×
[¿¼ÑÐ] 297Çóµ÷¼Á +4 ѧº£Æ¯²´ 2026-03-13 4/200 2026-03-14 11:51 by ÈÈÇéɳĮ
[¿¼ÑÐ] 0856²ÄÁÏÓ뻯¹¤301Çóµ÷¼Á +5 ÞÈÊø¹â 2026-03-13 5/250 2026-03-13 22:00 by ÐÇ¿ÕÐÇÔÂ
[˶²©¼ÒÔ°] 085600 260·ÖÇóµ÷¼Á +3 Ìì¿Õ»¹ÏÂÓêô 2026-03-13 5/250 2026-03-13 18:46 by Ìì¿Õ»¹ÏÂÓêô
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û